Skip to main content
eScholarship
Open Access Publications from the University of California

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

  • Author(s): Ashworth, Alan
  • Frankum, J
  • Moudry, P
  • Brough, R
  • Hodny, Z
  • Bartek, J
  • Lord, CJ
  • et al.

Published Web Location

http://europepmc.org/articles/PMC4484416?pdf=render
No data is associated with this publication.
Abstract

Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. By identifying novel predictive bioma

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item